Literature DB >> 16140964

Restoration of the expression of transporters associated with antigen processing in lung carcinoma increases tumor-specific immune responses and survival.

Yuanmei Lou1, Timothy Z Vitalis, Genc Basha, Bing Cai, Susan S Chen, Kyung Bok Choi, Andrew P Jeffries, W Mark Elliott, Derek Atkins, Barbara Seliger, Wilfred A Jefferies.   

Abstract

A wide variety of human carcinomas have low expression of tumor-associated antigen presentation in the context of MHC class I antigens due to defects in the antigen presentation pathway. This immune evasion mechanism renders many tumors unrecognizable by host immune surveillance mechanisms. The present study examines the expression of HLA, tapasin, transporter associated with antigen processing 1 (TAP1), and beta2 microglobulin in human small cell lung carcinoma and non-small cell lung carcinoma. Immunohistochemical staining showed severe impairment of the antigen presentation pathway in all patients. In order to recover tumor immunogenicity, a nonreplicating adenovirus expressing human TAP1 (AdhTAP1) was used to restore the expression of TAP1 in the antigen presentation pathway-deficient mouse lung carcinoma cell line, CMT.64. Infection of CMT.64 cells with AdhTAP1 increased MHC class I antigen surface expression, antigen presentation, and susceptibility to antigen-specific CTLs. Fluorescence-activated cell sorting and ELISPOT analysis showed that AdhTAP1 treatment significantly increased dendritic cell cross-presentation and cross-priming of tumor antigens. Furthermore, ex vivo and in vivo AdhTAP1 treatment significantly retarded tumor growth and increased survival of mice bearing CMT.64 tumors. Fluorescence-activated cell sorting analysis and immunohistochemical staining showed a significant increase in CD8+ and CD4+ T cells and CD11c+ dendritic cells infiltrating the tumors. The results show that TAP should be considered as a part of the immunotherapies for various cancers because it is likely to provide a general method for increasing immune responses against tumors regardless of the antigenic composition of the tumor or the MHC haplotypes of the host.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16140964     DOI: 10.1158/0008-5472.CAN-04-3977

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  28 in total

1.  Downregulation of tapasin expression in primary human oral squamous cell carcinoma: association with clinical outcome.

Authors:  Qian Jiang; Hong-ya Pan; Dong-xia Ye; Ping Zhang; Lai-ping Zhong; Zhi-yuan Zhang
Journal:  Tumour Biol       Date:  2010-06-08

2.  Identification of E2F1 as an important transcription factor for the regulation of tapasin expression.

Authors:  Juergen Bukur; Felix Herrmann; Diana Handke; Christian Recktenwald; Barbara Seliger
Journal:  J Biol Chem       Date:  2010-07-27       Impact factor: 5.157

3.  Expression of antigen processing and presenting molecules in brain metastasis of breast cancer.

Authors:  Yan Liu; Yoshihiro Komohara; Natalie Domenick; Masasuke Ohno; Maki Ikeura; Ronald L Hamilton; Craig Horbinski; Xinhui Wang; Soldano Ferrone; Hideho Okada
Journal:  Cancer Immunol Immunother       Date:  2011-11-08       Impact factor: 6.968

4.  A novel HLA-A*0201 restricted peptide derived from cathepsin G is an effective immunotherapeutic target in acute myeloid leukemia.

Authors:  Mao Zhang; Pariya Sukhumalchandra; Atim A Enyenihi; Lisa S St John; Sally A Hunsucker; Elizabeth A Mittendorf; Anna Sergeeva; Kathryn Ruisaard; Zein Al-Atrache; Patricia A Ropp; Haroon Jakher; Tania Rodriguez-Cruz; Gregory Lizee; Karen Clise-Dwyer; Sijie Lu; Jeffrey J Molldrem; Gary L Glish; Paul M Armistead; Gheath Alatrash
Journal:  Clin Cancer Res       Date:  2012-11-12       Impact factor: 12.531

5.  Loss of tapasin in human lung and colon cancer cells and escape from tumor-associated antigen-specific CTL recognition.

Authors:  Yosuke Shionoya; Takayuki Kanaseki; Sho Miyamoto; Serina Tokita; Ayumi Hongo; Yasuhiro Kikuchi; Vitaly Kochin; Kazue Watanabe; Ryota Horibe; Hiroshi Saijo; Tomohide Tsukahara; Yoshihiko Hirohashi; Hiroki Takahashi; Noriyuki Sato; Toshihiko Torigoe
Journal:  Oncoimmunology       Date:  2017-01-03       Impact factor: 8.110

6.  TAP1 down-regulation elicits immune escape and poor prognosis in colorectal cancer.

Authors:  Agnes Ling; Anna Löfgren-Burström; Pär Larsson; Xingru Li; Maria L Wikberg; Åke Öberg; Roger Stenling; Sofia Edin; Richard Palmqvist
Journal:  Oncoimmunology       Date:  2017-08-07       Impact factor: 8.110

7.  Identification of an epigenetic profile classifier that is associated with survival in head and neck cancer.

Authors:  Graham M Poage; Rondi A Butler; E Andrés Houseman; Michael D McClean; Heather H Nelson; Brock C Christensen; Carmen J Marsit; Karl T Kelsey
Journal:  Cancer Res       Date:  2012-04-16       Impact factor: 12.701

8.  CD40 induces antigen transporter and immunoproteasome gene expression in carcinomas via the coordinated action of NF-kappaB and of NF-kappaB-mediated de novo synthesis of IRF-1.

Authors:  Aristides Moschonas; Maria Kouraki; Pauline G Knox; Efstathia Thymiakou; Dimitris Kardassis; Aristides G Eliopoulos
Journal:  Mol Cell Biol       Date:  2008-08-11       Impact factor: 4.272

Review 9.  Targeted degradation of ABC transporters in health and disease.

Authors:  Daphne Nikles; Robert Tampé
Journal:  J Bioenerg Biomembr       Date:  2007-12       Impact factor: 2.945

10.  Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer.

Authors:  Barbara Seliger; Robert Stoehr; Diana Handke; Anja Mueller; Soldano Ferrone; Bernd Wullich; Andrea Tannapfel; Ferdinand Hofstaedter; Arndt Hartmann
Journal:  Cancer Immunol Immunother       Date:  2009-10-07       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.